ERBB2 and sarcoma: Ahmed et al. (2013) conducted a phase 1/2 clinical trial to evaluate the efficacy of CAR-T cell therapy in the treatment of relapsed/refractory human epidermal growth factor 2-positive sarcomas. HER2-specific chimeric antigen receptor-specific T cells with the CD28.ζ signaling domain were used with conditioning chemotherapy.